The EDN1 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population targeting the EDN1 gene in the HeLa human cervical adenocarcinoma cell line. This model enables loss-of-function studies of endothelin-1, a vasoactive peptide with potent mitogenic and vasoconstrictor activity. The polyclonal format provides a heterogeneous mix of gene-edited cells, ideal for pooled functional analyses without single-cell cloning.
HeLa cells are an immortalized epithelial cell line positive for HPV-18, derived from cervical cancer. Their robust growth, extensive characterization, and widespread use make them a foundational model in cancer biology, signal transduction, and drug discovery. The epithelial origin offers a relevant context for studying EDN1 in cervical and other carcinomas.
EDN1 encodes preproendothelin-1, processed by furin-like proteases and endothelin-converting enzyme-1 (ECE-1) to active endothelin-1. Secreted endothelin-1 binds to G protein-coupled receptors ETA and ETB, primarily coupling to Gq/G11 to activate PLC, generating IP3 and DAG, which mobilize calcium and activate PKC. This triggers MAPK/ERK and PI3K/AKT cascades, promoting proliferation and migration. Upstream, EDN1 is induced by proinflammatory cytokines (TNF-??, IL-1??), hypoxia (HIF-1??), angiotensin II, and TGF-??. Downstream, it upregulates transcription factors c-fos and c-jun and fibrotic genes (collagen, fibronectin).
In HeLa cells, endogenous EDN1 sustains autocrine/paracrine loops that may support tumorigenic phenotypes including enhanced proliferation, migration, and survival. Disrupting EDN1 eliminates this signaling, allowing dissection of its role in cervical cancer biology without pharmacological off-target effects. The polyclonal knockout minimizes clonal artifacts, enabling robust population-level assays.
Applications include validation of endothelin receptor antagonists (bosentan, ambrisentan), analysis of calcium flux and MAPK/ERK phosphorylation, proliferation (MTT, BrdU), migration, and invasion assays. These cells are also suitable for studying EDN1 loss on downstream targets via RT-qPCR, western blotting, ELISA, and AP-1 reporter assays. For further information, contact Ascent Research.
